Product Description
AZD1981 is a potent, fully reversible, functionally non-competitive antagonist of human CRTh2. AZD1981 blocks agonist-induced human eosinophil CD11b expression, shape change (including in whole blood), chemotaxis, basophil shape change and Th2-cell chemotaxis. AZD1981 is a weak inhibitor (>10muM) of CYP2C9, OATP1B1 and UGT1A1 as well as an inducer of CYP3A4 in vitro. (Sourced from: https://openinnovation.astrazeneca.com/clinical-research/clinical-molecules/azd1981.html)
Mechanisms of Action: CRTH2 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Chronic Obstructive Pulmonary Disease|Asthma|Urticaria
Phase 1: Healthy Volunteers|Asthma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NA_00089252 | P2 |
Completed |
Urticaria |
2016-01-01 |
|
| 2010-020407-73 | P2 |
Completed |
Asthma |
2012-02-16 |
|
| Sweapea | P2 |
Completed |
Asthma |
2012-02-01 |
|
| D9830C00020 | P1 |
Completed |
Healthy Volunteers |
2011-05-01 |